Showing results (191-200 of 235) with videos related to

Sort By:
Pageof 24
Biorxiv : the Preprint Server for Biology|February 6, 2026
Macrophage immunosenescence prolongs intraocular inflammation in aged mice via impaired induction of regulatory T cellsTaku Yamamoto, Keitaro Hase, Joseph B Lin, et al.
Molecular Cell|May 13, 2026
High-throughput screening approach identifies substrate-selective Hsp104 variants that counter amyloid seeding with diminished off-target effectsJeremy J Ryan, Karlie R Miller, Anuradhika Puri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2007
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinomaJ Lee, T Lim, J E Uhm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 29, 2013
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomasSang Y Ha, Jeeyun Lee, So Y Kang, et al.
Vaccine|November 26, 2009
Human rotavirus genotypes in hospitalized children, South Korea, April 2005 to March 2007S Y Lee, S K Hong, S G Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trialS T Kim, J H Kang, J Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Postoperative chemoradiotherapy for gastric cancerS H Park, D Y Kim, J S Heo, et al.
British Journal of Cancer|May 27, 2004
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's viewD H Lim, D Y Kim, M K Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>S H Park, D H Lim, T S Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2018
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patientsS T Kim, K C Banks, E Pectasides, et al.
Pageof 24